Literature DB >> 12364348

Goal-oriented hypertension management: translating clinical trials to practice.

Gregory M Singer1, Munavvar Izhar, Henry R Black.   

Abstract

Several clinical trials using a blood pressure (BP) treatment algorithm focused on a predetermined goal have achieved better control rates than those of national survey data. These trials reached the Sixth Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI) diastolic blood pressure (DBP) goal of <90 mm Hg in >90% of volunteers and systolic blood pressure (SBP) goal of <140 mm Hg in >60% of volunteers. We evaluated BP control of 437 consecutive patients after at least one year of follow up in a specialist clinic which employed "goal-oriented management," ie, treating to a specific BP goal without a formal drug treatment algorithm, to determine whether JNC VI goals could be achieved. Overall, 276 (63%) patients achieved SBP goal, with 376 (86%) at DBP goal and 358 (59%) at both goals. Only 23% of patients were on monotherapy, with 34% requiring 2 drugs and 37% requiring 3 or more medications. There was no substantial difference in BP control rates among age, gender, and ethnicity subgroups. However, in the 20% of patients who were diabetic, only 52% had a BP of <140 mm Hg and <90 mm Hg, whereas fewer (22% and 15%, respectively) achieved the more stringent goals of JNC VI and the American Diabetic Association (ADA)/National Kidney Foundation (NKF). Goal-oriented management achieved dramatically better control rates than what is reported. Although DBP control was easy to achieve, achieving SBP goal still remained difficult. Employing goal-oriented management can translate BP control results achieved in clinical trials into outpatient practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364348     DOI: 10.1161/01.hyp.0000035858.04434.03

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  21 in total

1.  Diagnosis and Control of Hypertension in the Elderly Populations of Japan and the United States.

Authors:  Yasuhiko Saito; Shieva Davarian; Atsuhiko Takahashi; Edward Schneider; Eileen M Crimmins
Journal:  Int J Popul Stud       Date:  2015-12-31

2.  Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.

Authors:  Roberto Fogari; Stefano Taddei; Merete Holm-Bentzen; Jacek Baszak; Lorenzo Melani; Kai Schumacher
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 3.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres.

Authors:  Y Valcárcel; R Jiménez; V Hernández; R Arístegui; A Gil
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.

Authors:  Hans R Brunner; Kikuo Arakawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 6.  Characterization and treatment of resistant hypertension.

Authors:  Roberto Pisoni; Mustafa I Ahmed; David A Calhoun
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

7.  Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.

Authors:  Massimo Volpe; Peter Brommer; Uwe Haag; Cristina Miele
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 8.  The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose ARB/CCB combinations in lowering levels of this preferential target.

Authors:  Jean-Jacques Mourad
Journal:  Vasc Health Risk Manag       Date:  2008

Review 9.  ASH position paper: Adherence and persistence with taking medication to control high blood pressure.

Authors:  Martha N Hill; Nancy H Miller; Sabina DeGeest
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-09-16       Impact factor: 3.738

10.  A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control.

Authors:  Barry L Carter; George R Bergus; Jeffrey D Dawson; Karen B Farris; William R Doucette; Elizabeth A Chrischilles; Arthur J Hartz
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.